28-04-2025, 20:23

Boehringer’s new zongertinib data demonstrate durable and clinically meaningful results in patients with HER2 (ERBB2)-mutant advanced NSCLC

Notified -
Globe Newswire28-04-2025, 20:23
19-02-2025, 19:05

Boehringer’s zongertinib receives Priority Review from U.S. FDA for the treatment of HER2 (ERBB2)-mutant advanced non-small cell lung cancer

Notified -
Globe Newswire19-02-2025, 19:05
22-10-2024, 19:00

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection
Globe Newswire22-10-2024, 19:00
9-09-2024, 22:45

Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients
Globe Newswire9-09-2024, 22:45
27-08-2024, 14:05

Boehringer Ingelheim to unveil groundbreaking oncology research at WCLC, demonstrating strength of portfolio
Globe Newswire27-08-2024, 14:05
26-06-2024, 19:10

A21 Launches Host Applications for Walk for Freedom 2024
Globe Newswire26-06-2024, 19:10
20-06-2024, 21:46

Rapafusyn Pharmaceuticals Secures $28 Million Series A to Advance Its Non-Degrading Molecular Glue Drug Discovery Platform
Globe Newswire20-06-2024, 21:46
4-03-2023, 03:03

Space Tea Set to Attend Natural Products Expo West 2023

Natural Products Expo West is the leading trade show in the natural, organic and healthy products industry, drawing
Globe Newswire4-03-2023, 03:03